Yuanwang Pan

Title: Innovations in Lung Cancer Treatment by Yuanwang Pan

Introduction

Yuanwang Pan is an accomplished inventor based in New York, NY (US). He has made significant contributions to the field of cancer treatment, particularly focusing on lung squamous cell carcinoma. His innovative approach aims to improve therapeutic outcomes for patients suffering from this aggressive form of cancer.

Latest Patents

Yuanwang Pan holds a patent for a method titled "Therapeutic targeting of mutant lung squamous cell carcinoma through RTK-RAS signaling inhibition." This patent outlines a treatment strategy for lung squamous cell carcinoma (LUSC) by administering one or more inhibitors of the RTK-Ras signaling pathway to individuals in need. The method specifically addresses LUSC cells that may carry a mutation in the KMT2D gene. The inhibitors mentioned in the patent include SHP2 inhibitors and epidermal growth factor receptor (EGFR) inhibitors. Furthermore, the patent suggests that combinations of SHP2 inhibitors and EGFR inhibitors can be effectively utilized.

Career Highlights

Yuanwang Pan is affiliated with New York University, where he conducts research and develops innovative treatment methods. His work has garnered attention for its potential to significantly impact the treatment landscape for lung cancer.

Collaborations

Yuanwang collaborates with esteemed colleagues, including Kwok-kin Wong and Han Han, who contribute to his research efforts and enhance the scope of his work.

Conclusion

Yuanwang Pan's innovative patent and research efforts represent a promising advancement in the treatment of lung squamous cell carcinoma. His work exemplifies the potential of targeted therapies in improving patient outcomes in oncology.